-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa Therapeutics To Present Interim Clinical Results From Ongoing Phase 1/2 Study Of GSPT1-Directed MGD MRT-2359 In mCRPC Patients In Live Conference Call On December 16

Benzinga·12/15/2025 21:03:56
Listen to the news

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients.